Emerging life sciences companies often struggle while planning and executing the go-to-market strategy for their products due to either the absence or under-preparedness of advanced analytics and commercial operations functions. For such reasons, launching a new drug for rare diseases can be a daunting project for an emerging pharma or biotech company. Delays in successfully launching the rare disease drug or inefficiently designed sales models can expose the sales teams to productivity issues and lead to significant business losses.
Read this case study to know more about Axtria’s consultative approach to designing a fair, uniform, and rewarding incentive plan for a yet-to-be-launched oncology orphan drug. The multi-pronged solution approach helped the sales team accelerate the go-to-market process and launch the orphan drug without delays.
This global IC solution helped the client achieve 100% problem-free execution, buy-in from the sales leadership, and pay-out predictability across all models.
Contact us at insights@axtria.com with any questions